Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole
Authors:
- 2 October 2017
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 58 (3) , 347-356
Abstract
Apatinib is a small‐molecule tyrosine kinase inhibitor that has been approved for the treatment of patients with advanced‐stage gastric cancer or gastroesophageal junction cancer who have progressed or recurred after at least 2 kinds of systemic chemotherapy. In vitro data indicate that cytochrome P450 (CYP) 3A4 is the primary CYP isoenzyme involved in the metabolism of apatinib. Pharmacokinetic drug–drug interactions of apatinib and (1) a CYP3A4 inducer (rifampin) or (2) a CYP3A inhibitor (itraconazole) were clinically evaluated in healthy volunteers. Compared with the single administration of apatinib, its coadministration with rifampin resulted in a 5.6‐fold plasma clearance (CL/F) and 83% decrease in plasma AUC0–t of apatinib. By contrast, coadministration with itraconazole reduced the CL/F of apatinib by 40% and increased its AUC0–t by 75%. In summary, a strong CYP3A4 inducer (rifampin) had a strong effect (>5‐fold) on the clinical pharmacokinetics of apatinib, whereas a strong CYP3A inhibitor (itraconazole 100 mg once a day) had a weak effect (1.25‐ to 2‐fold). Whether these effects are of clinical significance needs further research and information about the exposure–safety and exposure–efficacy relationship of apatinib.Keywords
Funding Information
- National Natural Science Foundation of China (81521005)
This publication has 23 references indexed in Scilit:
- Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case reportOncoTargets and Therapy, 2017
- Successful treatment with apatinib for refractory recurrent malignant gliomas: a case seriesOncoTargets and Therapy, 2017
- Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid TumorsClinical Pharmacokinetics, 2016
- Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancerInternational Journal of Cancer, 2014
- Metabolism and Pharmacokinetics of Novel Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor Apatinib in HumansDrug Metabolism and Disposition, 2013
- Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chromatography–tandem mass spectrometry and its application to a pharmacokinetic studyJournal of Chromatography B, 2012
- Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy ParticipantsThe Journal of Clinical Pharmacology, 2011
- Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptorAnnals of Clinical Microbiology and Antimicrobials, 2006
- Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjectsCancer Chemotherapy and Pharmacology, 2004
- Pharmacokinetic Interactions with RifampicinClinical Pharmacokinetics, 2003